SUPERNUS PHARMACEUTICALS, INC. (SUPN) Form 8-K — Aug 3, 2026
Supernus Pharmaceuticals announced a definitive agreement to merge with Indivior Pharmaceuticals in an all-stock merger of equals, aiming to create a diversified CNS biopharmaceutical company with significant scale and flexibility to pursue business development opportunities. The company reported strong financial results for the second quarter of 2026, with total revenues increasing 32% to $219.1 million driven by the growth of key products like Qelbree, GOCOVRI, and ONAPGO, prompting a raise in full-year revenue guidance to a range of $860 million to $890 million.
Key figures
- Revenue
- 219.1 million
- Guidance
- $860 - $890 million
- Net Income
- -58.4 million
- Revenue Yoy
- 32%
- Cash Position
- 372.1 million
- Onapgo Net Sales
- 13.5 million
- Qelbree Net Sales
- 89.2 million
- Intangible Impairment
- 54.9
- Zurzuvae Collaboration Revenue
- 35.4 million
Price after filing
Close on the filing date to close N calendar days later (from $45.61). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.